BioSpace News Archive

Marking a significant advance in infant safety, the U.S. Food and Drug Administration (FDA) has given De Novo approval to Happiest Baby’s SNOO Smart Sleeper.

Harrington Discovery Institute Center for Brain Health Medicines at University Hospitals and the Alzheimer’s Drug Discovery Foundation announce a joint request for proposal for the 2023 ADDF-Harrington Scholar Award.

Mitsubishi Tanabe Pharma Canada announced that Andy Zylak has been appointed as the new President, effective April 1, 2023.

Hemostemix Inc. (TSXV: HEM) (OTCQB: HMTXF) (FSE: 2VF0) (“Hemostemix” or the “Company”) is pleased to announce it is completing a second round of interviews with candidates who may join the company as Executive Vice President, Business Development.

Medigene AG (Medigene, FSE: MDG1, Prime Standard), an early stage immuno-oncology platform company focusing on the discovery and development of T cell immunotherapies for solid tumors, and the National Cancer Institute (NCI) will collaborate to evaluate the potential of Medigene’s proprietary T cell receptors (TCRs) to be used in new cell constructs for the treatment of solid tumors.

Semiconductor Research Corporation, a premier research and workforce development consortium, is announcing the launch of solicitation season.

Oncternal Therapeutics, Inc. announced a strategic reprioritization based on the rapidly changing commercial landscape for Bruton’s tyrosine kinase inhibitors.

Supernus Pharmaceuticals, Inc. announced that it has paid the total principal amount due of $402.5 million under its 0.625% Convertible Senior Notes due 2023, in addition to payment of the remaining outstanding interest due of $1.3 million.

BD, a leading global medical technology company, announced that Michelle Quinn has been named executive vice president and general counsel for the company, effective April 1.

MedMira Inc., reported on its financial results for the quarter ended January 31, 2023.